These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 2587522)

  • 1. [The level of glycosylated hemoglobin A1c in the erythrocytes of patients with diabetic angio- and polyneuropathies].
    Karabun PM
    Probl Endokrinol (Mosk); 1989; 35(5):33-7. PubMed ID: 2587522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum and erythrocyte magnesium levels in type I and type II diabetics.
    Vanroelen WF; Van Gaal LF; Van Rooy PE; De Leeuw IH
    Acta Diabetol Lat; 1985; 22(3):185-90. PubMed ID: 3907234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of the determination of glycosylated hemoglobins in diabetes mellitus].
    Grinshpun MN; Mazovetskiĭ AG; Galenok VA; Dikker VE
    Probl Endokrinol (Mosk); 1983; 29(6):80-5. PubMed ID: 6419224
    [No Abstract]   [Full Text] [Related]  

  • 4. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus.
    Demirtunc R; Duman D; Basar M; Bilgi M; Teomete M; Garip T
    J Diabetes Complications; 2009; 23(2):89-94. PubMed ID: 18358749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
    Hayashi R; Hayakawa N; Makino M; Nagata M; Kakizawa H; Uchimura K; Hamada M; Aono T; Fujita T; Shinohara R; Nagasaka A; Itoh M
    Diabetes Care; 1998 Apr; 21(4):672-3. PubMed ID: 9571366
    [No Abstract]   [Full Text] [Related]  

  • 6. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus.
    Ak G; Buyukberber S; Sevinc A; Turk HM; Ates M; Sari R; Savli H; Cigli A
    J Diabetes Complications; 2001; 15(3):150-7. PubMed ID: 11358684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of diabetic state and related disorders on the urinary excretion of magnesium and zinc in patients.
    el-Yazigi A; Hannan N; Raines DA
    Diabetes Res; 1993; 22(2):67-75. PubMed ID: 8205739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Glycosylated hemoglobin and diabetes mellitus].
    Leutenegger M; Poynard JP; Maquart FX; Borel JP
    Diabete Metab; 1982 Sep; 8(3):249-63. PubMed ID: 7141065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A clinical assessment of a colorimetric method for the determination of glycosylated hemoglobin--the diabetes test].
    Korolev VA; Pristupiuk AM; Glushkova OV; Dunaeva DD; Belokurenko VP; Malakhova OIu; Sapegin ID
    Lik Sprava; 2000; (5):96-8. PubMed ID: 11031463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid peroxidation and antioxidant enzyme levels in type 2 diabetics with microvascular complications.
    Kesavulu MM; Giri R; Kameswara Rao B; Apparao C
    Diabetes Metab; 2000 Nov; 26(5):387-92. PubMed ID: 11119018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Glycosylated hemoglobin as a prognostic index of the appearance of vascular complications in diabetic patients].
    Ezcurra Ferrer EJ; Licea Puig M; Díaz Díaz O
    Rev Clin Esp; 1990; 187(3):121-4. PubMed ID: 2284483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreasing complications in type 2 diabetes.
    Greenawald MH; Schaffer RS; Jeremiah MP
    J Fam Pract; 1998 Apr; 46(4):278-9. PubMed ID: 9564363
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma thrombomodulin: a marker for microvascular complications in diabetes mellitus.
    Gabat S; Keller C; Kempe HP; Amiral J; Ziegler R; Ritz E; Bergis KH; Wahl P; Nawroth P
    Vasa; 1996; 25(3):233-41. PubMed ID: 8795304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular factors in diabetic neuropathy: comment.
    Simpson LO
    Diabetologia; 1995 Jul; 38(7):872-3. PubMed ID: 7556993
    [No Abstract]   [Full Text] [Related]  

  • 15. Glycosylated hemoglobin (Hb AI) as an indicator of therapy effects in different clinical types of diabetes.
    Czech A; Tatoń J
    J Chronic Dis; 1983; 36(11):803-10. PubMed ID: 6643647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of macro- and microvascular disease as related to glycosylated hemoglobin in type I and II diabetic subjects. An epidemiologic study in Denmark.
    Nielsen NV; Ditzel J
    Horm Metab Res Suppl; 1985; 15():19-23. PubMed ID: 3908278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial.
    Kilpatrick ES; Rigby AS; Atkin SL
    Diabetes Care; 2008 Nov; 31(11):2198-202. PubMed ID: 18650371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble urokinase plasminogen activator receptor in type 1 diabetic children, relation to vascular complications.
    Sherif EM; El Maksood AAA; Youssef OI; Salah El-Din NY; Khater OKM
    J Diabetes Complications; 2019 Sep; 33(9):628-633. PubMed ID: 31301955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between plasma sialic acid concentration and microvascular and macrovascular complications in type 1 diabetes: the EURODIAB Complications Study.
    Crook MA; Pickup JC; Lumb PJ; Giorgino F; Webb DJ; Fuller JH;
    Diabetes Care; 2001 Feb; 24(2):316-22. PubMed ID: 11213885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycated hemoglobin in fractionated erythrocytes.
    Nakashima K; Nishizaki O; Andoh Y; Takei H; Itai A; Yoshida Y
    Clin Chem; 1989 Jun; 35(6):958-62. PubMed ID: 2731368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.